Supernus v. Ascent, Hetero & Camber: Trokendi XR® suit dismissed without prejudice in 94 days
Supernus Pharmaceuticals filed a 10-patent infringement action in the Eastern District of New York against three generic pharmaceutical defendants over Trokendi XR® (topiramate extended-release). The case ended in a voluntary dismissal without prejudice after just 94 days, before any defendant filed an answer or motion.
Ten-patent Trokendi XR® action exits EDNY before defendants respond
On 28 July 2023, Supernus Pharmaceuticals, Inc. filed suit in the U.S. District Court for the Eastern District of New York against Ascent Pharmaceuticals, Inc., Hetero Labs Limited, and Camber Pharmaceuticals, Inc. The complaint asserted infringement of ten U.S. patents — including US8298576B2, US9622983B2, US8663683B2, US8877248B1, US8889191B2, US10314790B2, US8298580B2, US8992989B2, US9555004B2, and US9549940B2 — all relating to the branded extended-release topiramate product Trokendi XR®.
The recorded basis of termination is 'Dismissed without Prejudice.' The docket order, entered by Judge Nusrat J. Choudhury on 30 October 2023, states the case is dismissed without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i) following Supernus's Notice of Voluntary Dismissal (ECF No. 10), noting that no defendant had filed an answer or a motion for summary judgment at the time of dismissal.
The 94-day duration and pre-answer exit are consistent with a strategic recalibration by the plaintiff — whether driven by settlement discussions, ANDA procedural developments, or a decision to refile — though the specific reasons are not disclosed in the available public record. Because dismissal was without prejudice, Supernus retains the right to reassert these patents against the same defendants in a subsequent action.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 94 days
94 days from filing to closure — well under the median ANDA/pharma patent case duration
US8298576B2 and 9 further patents — Trokendi XR® topiramate extended-release formulations
Any R&D or regulatory team developing a topiramate extended-release product — whether for an ANDA, 505(b)(2), or branded reformulation — faces exposure across ten distinct Supernus patents. Because this case ended without a merits ruling, none of these patents has been held invalid or not infringed. Product teams should treat the entire portfolio as active and enforceable when scoping freedom-to-operate risk.
Official order — verbatim text
The dismissal order confirms the procedural basis under Rule 41(a)(1)(A)(i) and records the without-prejudice character of the exit. Because no merits arguments were adjudicated, the order carries no implications for the validity or enforceability of the ten asserted patents. For Supernus, the order preserves full litigation optionality; for the defendants, it offers no protective legal effect.
Dismissed without prejudice: what the voluntary exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff's unilateral right to dismiss before answer
Fed. R. Civ. P. 41(a)(1)(A)(i) allows a plaintiff to voluntarily dismiss an action without a court order before the opposing party serves an answer or a motion for summary judgment. Because no defendant had done either, Supernus exercised this right as of right. Judge Choudhury's 30 October 2023 order confirmed the dismissal and its without-prejudice character.
Pre-answer voluntary dismissalWithout prejudice: Supernus preserves all patent claims for future action
A dismissal without prejudice does not adjudicate the merits and does not bar Supernus from refiling the same infringement claims against Ascent, Hetero Labs, or Camber at a later date. All ten asserted patents remain enforceable. The dismissal effectively resets the litigation clock without any adverse finding on validity or infringement.
Claims preserved; refiling permittedDefendants face continuing exposure under the same ten patents
Because the dismissal was without prejudice, Ascent, Hetero Labs, and Camber cannot treat this exit as a resolution. They received no covenant not to sue and no merits adjudication. If their ANDA approvals or commercial launch plans remain active, the risk of a subsequent infringement suit under these same patents persists. The specific terms of any parallel negotiations are not disclosed in the available record.
No merits ruling; exposure continuesGeneric topiramate ER launch timeline remains legally uncertain
For generic manufacturers seeking to launch topiramate extended-release products referencing Trokendi XR®, this dismissal without prejudice provides no clearance. The ten Supernus patents remain a live enforcement risk. Competitors and licensees in the extended-release CNS formulation space should treat this case as unresolved rather than as a signal of patent weakness.
No patent clearance createdFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Ascent Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Camber Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Nicholas Franks Giove | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New York Eastern District CourtSearch in Eureka ↗ |
R&D signals in the topiramate extended-release IP space
Forward-looking patent and innovation intelligence derived from the Supernus v. Ascent, Hetero & Camber dispute — covering portfolio activity, formulation filing trends, and competitive white space.
Supernus's topiramate ER patent estate: breadth and continuation risk
Supernus has assembled a ten-patent portfolio across multiple application families covering Trokendi XR®. This suggests active continuation filing strategy. Monitoring for newly issued continuations or divisionals from the parent applications could reveal additional claim sets that generic developers may need to design around or challenge via IPR.
Continuation filing watchExtended-release topiramate formulation filing trends and competitive density
Patent filing activity in extended-release anticonvulsant formulations has grown as branded players seek to extend exclusivity beyond core compound patents. Mapping filing density around topiramate ER dosage forms — including bead-in-capsule, matrix, and osmotic approaches — can reveal where generic and branded R&D teams are placing their innovation bets and where design-around space may exist.
Formulation filing densityAscent, Hetero Labs & Camber: generic topiramate IP and ANDA pipeline signals
Hetero Labs, as a vertically integrated generics manufacturer, holds its own active patent portfolio in pharmaceutical formulations. Tracking Hetero Labs' and Camber's patent filings in the extended-release CNS space may reveal proprietary formulation approaches developed to support ANDA paragraphs IV certifications and design-around strategies relative to Supernus's claims.
Generic defendant IP watchAdjacent R&D opportunity: next-generation topiramate delivery and CNS ER innovation
The concentration of Supernus's portfolio around current Trokendi XR® formulation parameters may leave adjacent white space in novel delivery mechanisms — such as sprinkle formulations for paediatric dosing, transdermal delivery, or combination CNS therapies involving topiramate. Early patent filing in these adjacencies could create defensible IP positions outside Supernus's existing claim perimeter.
Adjacent formulation white spaceSimilar ANDA patent infringement cases involving extended-release CNS formulations
Explore comparable topiramate and extended-release CNS formulation patent disputes filed in U.S. district courts, including ANDA-triggered multi-defendant infringement actions.
What this case signals for the topiramate ER patent enforcement landscape
A ten-patent pre-answer dismissal in pharma typically signals ongoing strategic repositioning — not a concession of patent weakness.
Pre-answer exit preserves maximum optionality for Supernus's enforcement strategy
By dismissing before any defendant answered, Supernus avoided any invalidity or non-infringement arguments entering the record. The without-prejudice dismissal keeps all ten patents fully deployable for future ANDA litigation or licensing negotiations against these and other generic filers.
Generic defendants should monitor ANDA status and parallel proceedings closely
A voluntary pre-answer dismissal in ANDA-related patent cases is frequently followed by refiling, settlement, or coordination with related district court or PTAB proceedings. Ascent, Hetero Labs, and Camber should track Supernus's broader patent portfolio activity for signals of next steps.
Supernus v Ascent — key questions answered
The case was dismissed without prejudice on 30 October 2023, pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). Supernus filed a Notice of Voluntary Dismissal before any defendant served an answer or motion for summary judgment. No merits ruling was issued on any of the ten asserted patents.
Supernus asserted ten US patents: US8298576B2, US9622983B2, US8663683B2, US8877248B1, US8889191B2, US10314790B2, US8298580B2, US8992989B2, US9555004B2, and US9549940B2, all relating to the extended-release topiramate product Trokendi XR®.
No. A dismissal without prejudice under Rule 41(a)(1)(A)(i) does not bar the plaintiff from refiling the same claims. Supernus retains the right to reassert all ten patents against Ascent, Hetero Labs, and Camber in a future action. The specific reasons for the dismissal are not disclosed in the available public record.
The without-prejudice dismissal provides no patent clearance for generic topiramate ER products. None of the ten asserted Supernus patents was held invalid or not infringed. Generic manufacturers with active or planned ANDAs referencing Trokendi XR® remain exposed to subsequent infringement suits under the same patent portfolio.
The case ended before any defendant filed an answer or motion for summary judgment, which is the procedural threshold for a unilateral voluntary dismissal under Rule 41(a)(1)(A)(i). The specific reasons driving Supernus's decision to dismiss at this early stage are not disclosed in the available public docket record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.